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Abstract: This is a comprehensive study of a large range of biometric
and optical parameters in people with type 1 diabetes. The parameters of
74 people with type 1 diabetes and an age matched control group were
assessed. Most of the people with diabetes had low levels of neuropathy,
retinopathy and nephropathy. Marginal or no significant differences were
found between groups for corneal shape, corneal thickness, pupil size,
and pupil decentrations. Relative to the control group, the diabetes group
demonstrated smaller anterior chamber depths, more curved lenses, greater
lens thickness and lower lens equivalent refractive index. While the optics
of diabetic eyes make them appear as older eyes than those of people of
the same age without diabetes, the differences did not increase significantly
with age. Age-related changes in the optics of the eyes of people with
diabetes need not be accelerated if the diabetes is well controlled.
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1. Introduction
Diabetes mellitus is a group of metabolic diseases characterized by chronic hyperglycemia.
It has multiple complications and premature morbidity and mortality. It is reaching epidemic
levels throughout the world, producing cardiovascular complications, eye and kidney diseases
and limb amputations. Reducing morbidity and mortality, and improving quality of life are
major public health goals. Diabetes affects the optics and biometry of the eye and blurriness of
vision is often the first sign of its presence [1]. This introduction highlights differences known
about the biometry of diabetic and non-diabetic eyes.
Several studies have reported greater central corneal thickness in adults and children with di-
abetes than in non-diabetic individuals [2–7], but some have not [8–11]. Wiemer et al. [8] found
smaller posterior radii of curvature in people with diabetes than in controls without differences
in anterior radius of curvature, and without effect on overall corneal power.
The natural pupil becomes smaller with increase in age [12,13] and is smaller in people with
diabetes than in those without diabetes, particularly at low light levels [14–19].
With increasing age, anterior chamber depth decreases and the lens becomes thicker, more
curved, and its equivalent refractive index decreases [20, 21]. These changes are more pro-
nounced in people with diabetes than in controls [22–31], and are dependent on diabetes dura-
tion [24,25]. Wiemer et al. [22] found the greater surface curvatures in diabetes were restricted
to people with type 1 diabetes (DM1). For DM1, Wiemer et al. [22] found the age-related
change in equivalent refractive index was nearly twice that of controls at −0.0007/year, but
this was balanced by steeper surface curvatures so that there was no significant change in lens
power. The decrease in equivalent refractive index in diabetic lens might be the result of the
change in refractive index distribution such as occurs in aging or to an overall decrease in
refractive index throughout the lens.
There are other changes in optics in diabetes that are probably related to the lens changes.
People with diabetes have lower amplitude of accommodation than age matched controls
[32–36], with estimates that diabetes duration is between 40% and 100% as important as age in
reducing amplitude [33,36–38]. The age-related decrease in ocular transmission at short wave-
lengths (or lens yellowing) is greater in people with diabetes than controls [39, 40]. It has been
reported that people with diabetes have greater higher-order aberrations than controls at fixed
pupil sizes [41, 42], although differences will be reduced under natural conditions because of
the smaller pupil sizes with diabetes.
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Previous studies of the biometry and optics of the eye in diabetes lead to the hypothesis
that eyes of people with diabetes act as older eyes than those of people of the same age with-
out diabetes. These studies were conducted on people with different types of diabetes, large
variations of glucose level, and large ranges of refractions. An accurate characterization of the
influence of long-term diabetes mellitus on the refractive components of the eye will assist
in modeling changes in visual performance and refractive status of diabetic patients. We have
therefore conducted a study on a cohort of type 1 diabetes participants with a limited range of
refractive errors. While there have been studies with larger numbers of people, this is the most
comprehensive study of a large range of biometric and optical parameters.
2. Methods
2.1. Participants
The study adhered to the tenets of the declaration of Helsinki. Ethical approval was obtained
from the Queensland University of Technology before the commencement of the study. All
participants provided written informed consent. The study had 74 participants (mean ± SD,
40 ± 12 years) with DM1 and 64 age-matched control participants (mean ± SD, 43 ± 12
years). Participants had case history, slit lamp biomicroscopy, intraocular pressure (I-Care) and
color vision assessment (Lanthony desaturated 15) as part of visual functions testing and ocular
health assessment. Blood was collected and analyzed for HbA1c levels in the laboratory, and
capillary blood glucose was measured with an Accu-Chek glucometer.
The majority of participants were recruited from the Longitudinal Assessment of Neuropathy
in Diabetes using novel ophthalmic Markers (LANDMark) study [43] at the Institute of Health
and Biomedical Innovation, for which DM1 participants tended to have low levels of the classic
triad of diabetic complications − neuropathy, retinopathy and nephropathy. In the LANDMark
study, people were examined for the eye on the side of hand dominance; as this testing involved
contact with the cornea, we examined the fellow eye on the same day where possible. If this
eye did not fulfil the criteria and the participant was able to return on another day, we tested the
better eye. For participants recruited outside the LANDMark study, the right eye was selected
where it fulfilled the criteria; otherwise the left eye was selected.
Criteria for inclusion were corrected visual acuities ≤ 0.1 log minimum angle resolution (log-
MAR), Pelli-Robson contrast sensitivity scores ≥ 1.65, equivalent spherical refraction ≤ ±3.5
D, and normal color vision. Exclusion criteria were more than mild diabetic retinopathy (e.g.
soft exudates, venous bleeding and/or severe retinal hemorrhage), retinal diseases, glaucoma,
uveitis, ocular trauma or surgery, epilepsy, endocrine disorders (except diabetes), hypertension,
neurological or psychiatric disorders, anemia, contact lens wear and cataract (posterior sub-
capsular, cortical and nuclear of grades higher than 1). Slit lamp photographs and C-Quant
values (straylight > 1.60 log(s) was excluded) were used to classify participants with and with-
out cataract on the basis of the lens opacity classification system III.
2.2. Data analysis
Analyses were performed with IBM SPSS Statistics version 21. Statistical significance was
set at p < 0.05 for all tests. Normality of data was determined by Kolmogorov-Smirnov and
Shapiro-Wilk tests. The Student unpaired t-test and the chi-square test determined significance
of differences between the two groups for non-categorical data and categorical data, respec-
tively. Results for these tests in Table 1 are the group means and 95% confidence intervals,
and the results in the text are the mean differences (control group subtracted from the diabetes
group) together with 95% confidence intervals. Multiple regression analysis was used to deter-
mine the combined effects of age and diabetes duration on ocular parameters but with gender
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and/or axial length as additional factors where these were significant according to simple lin-
ear regression. This analysis was done for the whole group, with duration for the participants
without diabetes given as zero, and for only the participants with diabetes. For linear fits of a
parameter as a function of age in figures, errors given are the standard errors. ANCOVA anal-
ysis was performed to determine the difference in age-related slopes for each ocular parameter
between diabetes and control groups.
2.3. Techniques
Objective refraction was obtained from the COAS-HD wavefront aberrometer (Wavefront Sci-
ences, Albuquerque, New Mexico, USA) using 2nd and 4th order Zernike polynomial coeffi-
cients for a 4 mm pupil. This has been found to be a reliable, accurate instrument for deter-
mining refraction [44]. It has an internal target which is kept optically beyond the refraction
point in order to relax accommodation. At least three sets of results were averaged to give the
spherical equivalent refraction. At least three eye images were taken with the aberrometer un-
der unaccommodated conditions. Pupil diameter and pupil decentration relative to the corneal
limbal centre, were determined [45,46]. Nasal and superior decentrations were given a positive
sign. Results were averaged.
The Medmont E-300 anterior corneal topographer was used for corneal topography. The
corneal height data corresponding to at least two images, having alignment quality specification
of ≥ 95%, were re-referenced from the keratometric axis to the pupil center of the aberrometer
images to determine conicoids
X2 +(1+Q)Z2 −2ZR = 0 (1)
where X and Y are axes perpendicular to the Z-axis passing through the line of sight, R is the
vertex radius of curvature and Q is the asphericity across a 6 mm diameter [20]. Results were
averaged. In addition, three good “quality value” images were taken with the Oculus Pentacam,
a two dimensional Scheimpflug camera system. As well as anterior corneal topography, these
images provided anterior and posterior corneal radii of curvatures, corneal central thickness,
and anterior chamber depth. Results were averaged.
Three distance measurements were taken for each participant with a partial coherence in-
terferometer, the Lenstar LS 900 (Haag−Streit, Ko¨niz, Switzerland). This gave corneal central
thickness, anterior chamber depth, lens thickness and axial length. Results were averaged. The
Pentacam also gave the corneal central thickness and anterior chamber depth.
Phakometry gave lens radii of curvature, equivalent refractive index and equivalent power.
The phakometer was based on the system developed by Tabernero et al. [47]. It moved on a
moveable breadboard relative to the participants who were supported by a forehead/chin rest.
The source was a semicircular ring of thirteen 890 nm LEDs 75 mm from the anterior cornea
(Fig. 1). Purkinje images were captured by a CCD camera with a telecentric lens. An organic
LED presented the fixation target through a Badal lens and beam splitter, and spherical equiva-
lent refraction (−8 to +3 D) of the participant was corrected by moving the OLED with respect
to the Badal lens. Image analysis was performed using custom built software to determine
heights of the Purkinje images PI (anterior cornea), PIII (anterior lens), and PIV (posterior
lens).
Lens radii of curvature and equivalent refractive index were estimated by a merit function
MF = MF1 +MF2 +MF3 = (Vthe −Vexp)2 +(h3the −h3exp)2 +(h4the −h4exp)2 (2)
MF is the combination of components MF1, MF2 and MF3. MF1 is the square of the difference
between experimental Vexp and theoretical vitreous length Vthe obtained from ray tracing into
the eye to the retina. MF2 is the squares of the difference between experimental PIII height
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Fig. 1. Phakometer
h3exp and theoretical PIII height h3the obtained from ray tracing into- and then out-of-the-eye
after reflection from the anterior lens surface. MF3 is the squares of the difference between
experimental PIV height h4exp and theoretical PIII height h4the obtained from ray tracing into-
and then out-of-the-eye after reflection from the posterior lens surface.
A program was written to minimize the merit function by manipulating lens radii of curvature
and equivalent refractive index. The merit function stopped after 2000 cycles or when the differ-
ence between successive estimates was less than 0.01%, depending on which came first (nearly
always the latter). The program used a four refracting-surface model eye. Refractive indices at
555 nm were those of the Gullstrand number 1 eye: 1.376, 1.336 and 1.336 for cornea, anterior
chamber and vitreous chamber, respectively. Refractive indices for wavelength 890 nm were
determined from dispersion equations provided by Atchison & Smith [48]: 1.36822, 1.32829
and 1.32855, respectively. Atchison & Smith also provided a correction to the refraction:
Rx890 = Rx550 +0.839 (3)
The Lenstar instrument gives a default axial length by subtracting 200 μm from the length
measured to the retinal pigment epithelium; this 200 μm was reinstated because the photore-
ceptor position rather than the internal limiting membrane is relevant for refraction. Corneal
thickness, anterior chamber depth and lens thickness for the model were obtained from the
Lenstar, and the vitreous depth was determined from these and the modified axial length. An-
terior and posterior corneal radii of curvature were obtained from the Oculus Pentacam.
After the lens radii of curvature and lens equivalent index were determined, an estimate of
lens refractive index at 555 nm was made. From equations for the different media [48], a linear
relationship between the lens indices at the two wavelengths was
nL555 = 1.0262nL890 −0.0273 (4)
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Lens equivalent power Fe at 555 nm was calculated from
Fe = FL1 +FL2 − tL
nL
FL1FL2 (5)
where nL is lens refractive index at 555 nm, tL is lens thickness, and FL1 and FL2 are front and
back surface powers
FL1 = (nL −na)/rL1 , FL2 = (nv −nL)/rL2 (6)
where na and nv are refractive indices of aqueous and vitreous at 555 nm, and rL1, and rL2 are
radii of curvature of the lens front and back surfaces.
3. Results
3.1. Characteristics of groups and summary of results
Table 1 shows characteristics of the groups. Five participants from the diabetes group had poor
phakometry images and were excluded from corresponding analyses. Due to limited time avail-
ability, the Medmont corneal topographer was not used with 39 participants, and a further five
participants had poor images and were excluded from corresponding analyses. There is no
significant difference in spherical equivalent refraction and corrected visual acuity between
groups, but log contrast sensitivity is slightly higher in the control group than in the diabetes
group.
Figure 2 shows the association between diabetes duration and age. There is a significant
linear relationship (slope +0.38, p < 0.001), but correlation is low (R2 0.18). Some older par-
ticipants have had diabetes for only a short time e.g. the cluster of 3 people with ages 58 - 62
years and durations less than 5 years.
3.2. Ocular biometry
Table 2 shows multiple regression fits for biometric and other parameters, both for the whole
group and for the diabetes group alone. The emphasis was on diabetes duration and age as fac-
tors, but axial length and gender were included where they had significant effects in regression
fits that includes diabetes duration and/or age; otherwise no factors are shown.
Figure 3 shows biometric parameters as a function of age for the diabetes and control groups.
Fits from the Wiemer study [22] are shown in Figs. 3(f), (h) and (i), and will be mentioned in
the Discussion.
Fig. 2. Diabetes duration as a function of age.
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Table 1. Parameters of participant groups. P-values are bolded where there are significantly
differences between groups. Errors are 95% confidence intervals.
Parameters and numbers in groups Diabetes group Control group P-values
(diabetes/control)
Number of eyes (R/L), (74/64) 48/26 54/10
Gender (F/M) (74/64) 30/44 44/20 0.001
Age (mean ± SD, age range in years), 40 ± 12, 19−63 43 ± 12, 20−62 0.77
(74/64)
Visual acuity (LogMAR), (74/64) −0.02 ± 0.05 −0.04 ± 0.05 0.55
Log contrast sensitivity, (74/64) 1.81 ± 0.03 1.89 ± 0.03 < 0.001
Spherical equivalent refraction (D), −0.58 ± 0.26 −0.44 ± 0.24 0.44
aberrometer (74/64)
Anterior corneal radius of curvature (mm), +7.76 ± 0.05 +7.82 ± 0.07 0.15
Pentacam (74/64)
Anterior corneal radius of curvature (mm), +7.73 ± 0.06 +7.78 ± 0.07 0.24
Medmont (47/47)
Anterior corneal asphericity Q, (47/47) −0.06 ± 0.04 −0.07 ± 0.04 0.86
Corneal centre thickness (mm), 0.545 ± 0.007 0.537 ± 0.011 0.26
Pentacam (74/64)
Corneal centre thickness (mm), 0.542 ± 0.007 0.537 ± 0.009 0.37
Lenstar (74/64)
Posterior corneal radius of curvature (mm), +6.36 ± 0.06 +6.43 ± 0.07 0.07
(74/64)
Anterior chamber depth (mm), 2.75 ± 0.09 2.86 ± 0.09 0.09
Pentacam (74/64)
Anterior chamber depth (mm), 2.74 ± 0.09 2.89 ± 0.09 0.03
Lenstar (74/64)
Pupil diameter (mm), (74/64) 5.96 ± 0.21 6.22 ± 0.21 0.08
Pupil decentration along x-axis (mm), +0.17 ± 0.15 +0.30 ± 0.12 0.19
(47/47)
Pupil decentration along y-axis (mm), +0.11 ± 0.10 +0.16 ± 0.09 0.43
(47/47)
Anterior lens radius of curvature (mm), +9.53 ± 0.26 +10.62 ± 0.29 < 0.001
(67/62)
Posterior lens radius of curvature (mm), −5.89 ± 0.18 −6.32 ± 0.19 <0.01
(67/62)
Lens equivalent refractive index, 555nm, 1.426 ± 0.003 1.431 ± 0.003 < 0.01
(67/62)
Lens central thickness (mm), Lenstar 4.31 ± 0.11 4.01 ± 0.09 < 0.001
(74/64)
Lens equivalent power (D), 555 nm 25.06 ± 0.80 24.28 ± 0.59 0.13
(67/62)
HbA1c (m mol), (74/64) 7.80 ± 0.26 5.03 ± 0.08 < 0.001
Blood glucose level (m mol), (74/64) 9.30 ± 0.78 − −
Diabetes duration (years) 19 ± 9 − −
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Table 2. Multiple regression fits for the whole group and for the diabetes group alone. No
coefficients appear where both diabetes duration and age are not significant factors.
Parameter Group Duration Age Axial length Constant R2
(years) (years) (mm) (D, mm, -)
Spherical equivalent whole group +0.020 −0.538 +11.45 0.24
refraction (D) diabetes group +0.025 −0.660 +14.11 0.29
Anterior corneal radius of whole group
curvature(mm), Pentacam diabetes group
Anterior corneal radius of whole group
curvature (mm), Medmont diabetes group
Anterior corneal whole group
asphericity Q diabetes group +0.004 −0.68 0.15
Corneal centre thickness whole group +0.0005 +0.552 0.04
(mm), Pentacam diabetes group
Corneal centre thickness whole group
(mm), Lenstar diabetes group
Posterior corneal radius of whole group
curvature (mm) diabetes group
Anterior chamber depth whole group −0.009 −0.010 +0.147 −0.21 0.43
(mm), Pentacam diabetes group −0.016 −0.007 +0.146 −0.12 0.54
Anterior chamber depth whole group −0.009 −0.010 +0.147 −0.21 0.43
(mm), Pentacam diabetes group −0.016 −0.007 +0.146 −0.12 0.54
Anterior chamber depth whole group −0.008 −0.011 +0.179 −0.87 0.46
(mm), Lenstar diabetes group −0.013 −0.010 +0.187 −1.00 0.56
Pupil diameter (mm) whole group −0.029 +0.280 +0.76 0.29
diabetes group −0.025 +0.305 −0.07 0.24
Pupil decentration along whole group
x-axis/y-axis (mm) diabetes group
Anterior lens radius of whole group −0.045 −0.026 +0.460 +0.72 0.47
curvature (mm) diabetes group −0.040 +0.418 +0.98 0.40
Posterior lens radius of whole group +0.017 +0.012 −0.270 −0.35 0.25
curvature (mm) diabetes group
Lens central thickness, whole group +0.016 +0.021 −0.091 +5.35 0.73
Lenstar (mm) diabetes group +0.020 +0.021 −0.113 +5.69 0.77
Lens equivalent refractive whole group −0.0003 −0.0004 −0.0033 +1.525 0.35
index diabetes group −0.0003 −0.0041 +1.537 0.28
Lens equivalent power (D) whole group −0.046 −1.997 +73.70 0.59
diabetes group
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Figure 3(a) shows spherical equivalent refraction. There is no significant age-related slope for
either group, and the slope difference between groups is also not significant. However age and
axial length, although not diabetes duration, contribute significantly to the multiple regression
fits. The mean difference in refraction between groups is not significant.
Results for anterior corneal radius of curvature are similar for the Medmont topographer and
Oculus Pentacam (Tables 1 and 2). The relationship between radius of curvature and age is
not significant for either group and slope differences between the groups are not significant.
Neither age nor diabetes duration contribute significantly to the multiple regression fits. The
mean differences in radius of curvature between groups are not significant.
Figure 3(b) shows Medmont-determined anterior corneal asphericity. There is a significant
positive age-related slope for the diabetes group (+0.004/year, R2 0.14, p 0.01), but the slope
difference between groups is not quite significant (p 0.08). Age contributes significantly to the
multiple regression fit for the diabetes group alone, and diabetes duration does not contribute
significantly to either multiple regression fit. The mean difference in asphericity between groups
is not significant.
Results for corneal central thickness are presented here mainly for the Lenstar (Fig. 3(c)),
but results for the Oculus Pentacam are similar (Table 1). There is no significant age-related
slope for either group, and the slope difference between groups is not quite significant (p 0.07).
Neither age nor diabetes duration contributes significantly to the multiple regression fits. The
mean difference in thickness between the groups is not significant.
The relationship between posterior corneal radius of curvature and age is not significant for
either group and the slope difference between groups is not significant. Neither age nor diabetes
duration contributes significantly to the multiple regression fits. The mean difference in radius
of curvature between the groups approaches significance (−0.08 ± 0.08 mm, p 0.07).
Results for anterior chamber depth are presented here mainly for the Lenstar (Fig. 3(d)), but
results for the Pentacam are similar (Tables 1 and 2). For each group there is a significant age-
negative related slope (−0.013 and −0.010 mm/year for diabetes and control groups, respec-
tively), but the slope difference between groups is not significant. Diabetes duration, age and
axial length contribute significantly to the multiple regression fits. The diabetes group has sig-
nificantly shallower anterior chamber depths than the control group (mean difference −0.14 ±
0.13 mm, p 0.03).
Figure 3(e) shows pupil diameter. For each group there is a significant negative age-related
slope (−0.024 and −0.029 mm/year for diabetes and control groups, respectively), but the
slope difference between groups is not significant. Age, but not diabetes duration, contributes
significantly to the multiple regression fits. The mean difference in pupil diameter between the
groups (−0.26 ± 0.30 mm) is not quite significant (p 0.08).
The relationships between pupil decentration components and age are not significant for ei-
ther group and slope differences between groups are not significant. Neither age nor diabetes
duration contributes significantly to the multiple regression fits. The mean differences in decen-
tration components between groups are not significant.
Figure 3(f) shows anterior lens radius of curvature. For each group there is a significant neg-
ative age-related slope, i.e. radius of curvature is smaller with increase in age (−0.024 and
−0.043 mm/year for diabetes and control groups, respectively), but the slope difference be-
tween groups is not significant. Diabetes duration, age and axial length contribute significantly
to the multiple regression fit for the whole group, but age is omitted for the diabetes group.
The diabetes group has significantly smaller radii of curvature than the control group (mean
difference −1.09 ± 0.40 mm, p < 0.001).
Figure 3(g) shows posterior lens radius of curvature. For the control group only, there is a
significant positive age-related slope, i.e. radius of curvature is smaller with increase in age
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(+0.023 mm/year), but the slope difference between groups is not quite significant (F1,125 =
3.36, p 0.07). Diabetes duration, age and axial length contribute significantly to the multiple
regression fit for the whole group, but neither contributes for the diabetes group alone. The
diabetes group has smaller radii of curvature than the control group (mean difference +0.43 ±
0.26 mm, p < 0.01).
Figure 3(h) shows lens central thickness. For each group there is a significant positive age-
related slope (+0.027 and +0.021 mm/year for diabetes and control groups, respectively), but
the slope difference between groups is not quite significant (p 0.11). Diabetes duration, age
and axial length contribute significantly to the multiple regression fits. The diabetes group has
greater lens thickness than the control group (mean difference +0.29 ± 0.15 mm, p < 0.001).
Figure 3(i) shows lens equivalent refractive index. For each group there is a significant neg-
ative age-related slope (−0.00033 and −0.00056/year for diabetes and control groups, respec-
tively), but the slope difference between groups is not quite significant (p 0.08). Diabetes du-
ration, age and axial length contribute significantly to the multiple regression fit for the whole
group, but age is omitted for the diabetes group. The diabetes group has lower equivalent index
than the control group (mean difference −0.006 ± 0.004, p < 0.01).
Figure 3(j) shows lens equivalent power. For each group there is a negative age-related slope,
which is significant for the control group (−0.052 D/year, p 0.02) but is not quite significant
for the diabetes group (−0.056 D/year, p 0.06), and the slope difference between groups is
not significant. Age and axial length contribute significantly to the multiple regression fit for
the whole group, but neither age nor diabetes contributes for the diabetes group. The mean
difference in power between groups is not significant.
4. Discussion
Considering the results shown in Tables 1 and 2, in Fig. 3 and across the different statistical
tests, the biometric parameters can be classified into four categories: A) parameters that are
not influenced by age nor by diabetes, B) parameters that are influenced by age but not by
diabetes, C) parameters that are influenced by both age and diabetes, but diabetes does not
affect the rate of change with age, and D) parameters that are influenced by both age and
diabetes, with diabetes increasing the rate of change with age. Parameters in category A are the
corneal parameters of anterior and posterior surface radii of cornea, anterior surface asphericity
and central thickness, and the pupil decentrations. Parameters in category B are the spherical
equivalent refraction, pupil diameter and lens equivalent power. Parameters in category C are
anterior chamber depth, anterior and posterior lens radii of curvature, lens thickness and lens
equivalent refractive index. There are no parameters in category D. It appears likely that in
some cases one parameter might have moved to another category concerning the influence of
diabetes if there had been more participants.
For category A parameters, the results agree with Wiemer et al. [8] concerning anterior radius
of curvature and with the studies that have found central corneal thickness does not change with
diabetes [8–11]. The results do not agree with Wiemer et al. [8] concerning posterior radius of
curvature. They found a significant difference between groups of −0.14 ± 0.08 mm compared
with −0.08 ± 0.08 mm here (p = 0.07). A power analysis of our results using α 0.05 and power
0.8 indicates that 159 participants per group are needed to show significance. While we have
put anterior corneal asphericity in category A, we note that it changes significantly with age for
the diabetes group.
For category B parameters, the spherical equivalent is representative of the hypermetropic
shift that occurs during adulthood [49, 50] (Fig. 3(a)). We have put pupil diameter in this cat-
egory, although the influence of diabetes is marginally significant (p = 0.08) and the literature
indicates that pupil size is smaller in the presence of diabetes [14–19]. A power analysis indi-
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(g) (h)
(i) (j)
Fig. 3. Relationships between parameters and age for diabetes and control groups. (a) spher-
ical equivalent refraction, (b) anterior corneal asphericity; (c) corneal central thickness, (d)
pupil diameter, (e) anterior chamber depth, (f) anterior lens radius of curvature, (g) poste-
rior lens radius of curvature, (h) lens central thickness, (i) lens equivalent refractive index,
and (j) lens equivalent power. Fits for diabetes type 1 participants are included from the
Wiemer et al. study [22] in (f), (h) and (i).
cates that 100 participants per group are needed to show significance. For lens power, we find
a reduction with age (−0.05 D/ year) (Fig. 3(j)). This is consistent with the study of Atchison
et al. [20] (−0.03 D/year) using similar instrumentation with a non-diabetic group, but Wiemer
et al. [22] did not find a trend.
For category C parameters, we find the effects of diabetes as follows: anterior chamber depth
is smaller (Fig. 3(d)), the lens surface radii of curvature are smaller (Fig. 3(f) and (g)), the
lens is thicker (Fig. 3(h)), and the equivalent refractive index is lower (Fig. 3(i)). These effects
correspond to the directions occurring with increasing age, and have been found in previous
studies with diabetes type I participants [22, 24]. However, the previous studies found acceler-
ated aging trends in the presence of diabetes for anterior chamber depth, anterior lens surface
radius of curvature and lens thickness, and, in the study of Wiemer et al. for the posterior lens
surface radius of curvature and equivalent refractive index. For these studies, these parameters
would be in our category D.
As one example of comparison between our study and that of Wiemer et al., our non-
significant difference in age-related rate of change between diabetes and control groups for
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anterior chamber depth was −0.003/year, compared with −0.009 ± 0.008 mm/year for the
Wiemer et al. study. Other comparisons between the respective studies are: anterior lens radius
of curvature +0.019 mm/year (not significant, ns) and −0.037 ± 0.027 mm/year (Fig. 3(f));
posterior lens radius of curvature −0.018 mm/year (ns) and +0.023 ± 0.021 mm/year; lens
thickness +0.006 mm/year (ns) and +0.020 ± 0.008 mm/year (Fig. 3(h)); equivalent refractive
index +0.00023/year (ns) and −0.0003 ± 0.0002/year (Fig. 3(i)).
There are several differences between methods and the participants between this and the
studies by Wiemer et al. [8, 22] and Sparrow et al. [24] which may account in large part for
differences in results. The previous studies used Scheimpflug imaging for all of their lenticular-
related parameters, while we used phakometry. Wiemer et al. included participants with ad-
vanced stage retinopathy, and it is likely that this was the case for Sparrow et al. who did not
exclude on the basis of retinopathy. Wiemer et al. had a large range of refractions for both di-
abetes and control groups (−10 to +6 D), while Sparrow et al. did not indicate any limitation
in refraction. This study included participants with no more than minimal diabetic retinopathy
and had a restricted range of refraction for both diabetes and control groups (−3 to +2 D).
This investigation indicates that people with well-controlled diabetes relative to neuropathy
and who are striving to remain compliant with health/lifestyle/medications, given that they were
monitored annually in the LANDMark study, need not have accelerated changes in the optics
of the eye with aging, and presumably the serious consequences of diabetes can be slowed.
The results reported here form part of a study into the ocular optics of people with type 1
diabetes. We found lower amplitude of accommodation in people with diabetes than in age-
matched controls, with the estimate that people with diabetes will experience presbyopia a few
years earlier in life than people without diabetes [36]. Results for parameters of straylight, lens
yellowing, ocular aberrations and lens shape and refractive index distribution will be reported
later.
The study has limitations. The diabetes group may be considered to be “well controlled”.
While this might be considered to be a strength in that we were dealing with a relatively ho-
mogenous group, it is a weakness in that differences between people with and without diabetes
were not as marked as would have been otherwise expected, especially concerning the influ-
ence of diabetes on rates of change of parameters with age as discussed above. As discussed
earlier, sample sizes were insufficient for some tests. As cycloplegia was not used in the study,
it is possible that some younger participants exerted some accommodation during tests which
would affect results; the age balance between the groups moderates this influence when com-
paring the groups for parameters.
5. Conclusions
These findings support the hypothesis that eyes of people with diabetes act as older eyes than
those of people of the same age without diabetes. However, the differences have not increased
significantly with age in this study. Relative to a control group, a type 1 diabetes group has
demonstrated smaller anterior chamber depths, more curved lenses, greater lens thickness and
lower lens equivalent refractive index. Marginal or no significant differences have been found
for corneal shape, corneal thickness, pupil size, and pupil decentrations. As nearly all of the di-
abetes participants have low levels of neuropathy, retinopathy and nephropathy, it is concluded
that age-related changes in the optics of the eyes of people with diabetes need not be accelerated
if the diabetes is well controlled.
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